Cargando…

Malignancy validation in a United States registry of rheumatoid arthritis patients

BACKGROUND: Physician reporting is commonly used to ascertain adverse events or outcomes measured in epidemiologic studies. However, little is known on the accuracy of physician reported malignancies compared to pertinent medical record review in large cohort studies. METHODS: The Consortium of Rheu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fisher, Mark C, Furer, Victoria, Hochberg, Marc C, Greenberg, Jeffrey D, Kremer, Joel M, Curtis, Jeff R, Reed, George, Harrold, Leslie, Solomon, Daniel H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3403943/ https://www.ncbi.nlm.nih.gov/pubmed/22651246 http://dx.doi.org/10.1186/1471-2474-13-85

Ejemplares similares

Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry
por: Harrold, Leslie R., et al.
Publicado: (2016)

Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis
por: Lillegraven, Siri, et al.
Publicado: (2019)

The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor
por: Harrold, Leslie R, et al.
Publicado: (2015)

Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations
por: Harrold, Leslie R., et al.
Publicado: (2016)

Comparative effectiveness and safety of rituximab versus subsequent anti–tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti–tumor necrosis factor therapies in the United States Corrona registry
por: Harrold, Leslie R., et al.
Publicado: (2015)

Risk of Infection Associated With Subsequent Biologic Agent Use After Rituximab: Results From a National Rheumatoid Arthritis Patient Registry
por: Harrold, Leslie R., et al.
Publicado: (2016)

Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry
por: Harrold, Leslie R., et al.
Publicado: (2017)

Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry
por: Harrold, Leslie R., et al.
Publicado: (2019)

Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis
por: Harrold, Leslie R., et al.
Publicado: (2017)

The rheumatoid arthritis treat-to-target trial: a cluster randomized trial within the Corrona rheumatology network
por: Harrold, Leslie R, et al.
Publicado: (2014)

Prevalence of Sjögren’s syndrome associated with rheumatoid arthritis in the USA: an observational study from the Corrona registry
por: Harrold, Leslie R., et al.
Publicado: (2020)

Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis
por: Harrold, Leslie R., et al.
Publicado: (2018)

Characteristics Associated with Biologic Monotherapy Use in Biologic-Naive Patients with Rheumatoid Arthritis in a US Registry Population
por: Pappas, Dimitrios A., et al.
Publicado: (2015)

“Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients”
por: Pappas, Dimitrios A, et al.
Publicado: (2014)

Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2017)

One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry
por: Harrold, Leslie R., et al.
Publicado: (2018)

Dual Biologic Therapy in Patients with Rheumatoid Arthritis and Psoriatic Arthritis
por: Furer, Victoria, et al.
Publicado: (2023)

Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and Sjögren’s syndrome enrolled in a large observational US registry
por: Harrold, Leslie R., et al.
Publicado: (2020)

Delays in Initiation of Disease-Modifying Therapy in Rheumatoid Arthritis Patients: Data from a US-Based Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2015)

Cluster‐Randomized Trial of a Behavioral Intervention to Incorporate a Treat‐to‐Target Approach to Care of US Patients With Rheumatoid Arthritis
por: Harrold, Leslie R., et al.
Publicado: (2018)

Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2021)

Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
por: Kavanaugh, Arthur, et al.
Publicado: (2018)

A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis
por: Smitten, Allison L, et al.
Publicado: (2008)

Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritis
por: Reed, George W., et al.
Publicado: (2017)

Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry
por: Strand, Vibeke, et al.
Publicado: (2017)

Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis
por: Simon, Teresa A., et al.
Publicado: (2015)

Time‐Varying Association of Rheumatoid Arthritis Disease Activity to Subsequent Cardiovascular Risk
por: Yoshida, Kazuki, et al.
Publicado: (2022)

Erratum to: Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis
por: Simon, Teresa A., et al.
Publicado: (2016)

Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry
por: Kremer, Joel M., et al.
Publicado: (2021)

Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment
por: Simon, T A, et al.
Publicado: (2009)

Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry
por: Mease, Philip J, et al.
Publicado: (2015)

Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2020)

Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from Two Corrona Registries
por: Mease, Philip J., et al.
Publicado: (2019)

Rheumatologist and Patient Mental Models for Treatment of Rheumatoid Arthritis Help Explain Low Treat‐to‐Target Rates
por: Hsiao, Betty, et al.
Publicado: (2022)

Barriers to treatment optimization and achievement of patients’ goals: perspectives from people living with rheumatoid arthritis enrolled in the ArthritisPower registry
por: Gavigan, Kelly, et al.
Publicado: (2020)

Understanding Heterogeneity in Patients’ Conceptualisation of Treatment for Rheumatoid Arthritis: A Cluster Analysis
por: Hsiao, Betty, et al.
Publicado: (2023)

A Model to Predict Future Biologic or Targeted Synthetic DMARD Switch at a Subsequent Clinic Visit in Rheumatoid Arthritis
por: Cappelli, Laura C., et al.
Publicado: (2023)

Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP+
por: Harrold, Leslie R., et al.
Publicado: (2023)

Evaluation of an Intervention to Support Patient‐Rheumatologist Conversations About Escalating Treatment in Patients with Rheumatoid Arthritis: A Proof‐of‐Principle Study
por: Danila, Maria I., et al.
Publicado: (2021)

The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry
por: Padula, Anthony S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t5dl9c5m9ouj47996m7tlkcg4k